MELT-300 demonstrated in a pivotal phase 3 study positive topline results in IV- and opioid-free procedural sedation for patients undergoing cataract surgery, according to a press release from Melt Pharmaceuticals.
“Building on the success of MKO Melt, a widely used compounded formulation that laid the groundwork for MELT-300, this innovative product represents a transformative step forward in procedural sedation for patients during cataract surgery,” Larry Dillaha, MD, CEO of Melt Pharmaceuticals, told Healio.
MELT-300, a single tablet delivered sublingually using Catalent’s